A disruptive technology for vaccines manufacturing based on Self-Assembled Polymeric Nanoparticulate systems

Project Information

SAP-Nano

Grant agreement ID: 728455

DOI

10.3030/728455

Project closed

EC signature date 21 May 2016

Start date 1 June 2016

End date 30 November 2016

Funded under

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

BIONANOPLUS SL
Spain

Periodic Reporting for period 1 - SAP-Nano (A disruptive technology for vaccines manufacturing based on Self-Assembled Polymeric Nanoparticulate systems)

Reporting period: 2016-06-01 to 2016-11-30

Summary of the context and overall objectives of the project

The SAP-Nano project by Bionanoplus S.L. was approved within the call for SME Instrument H2020, Topic NMP-25-2015: Accelerating the uptake of nanotechnologies, advanced materials or advanced manufacturing and processing technologies by SMEs, Call 2016-02-24.
Bionanoplus detected the major problems faced by many pharmaceutical, veterinary and cosmetic sector manufacturers to develop products using nanotechnology.
Bionanoplus has solved the scalability problem of traditional nanoparticle manufacturing methods avoiding the use of volatile organic solvents, thus it ensures an easy and inexpensive production of any scale, which can be performed using standard equipment and techniques.
SAP-Nano technology allows vaccine manufacturers to produce very effective vaccines without using the traditional adjuvants, avoiding the side effects these have.
On the other hand, PRRSV is the major cause of reproductive and respiratory problems in pigs worldwide. It is endemic in Europe and other parts of the world. It was estimated that losses due to PRRSV cost the swine industry EUR 1.5 billion per year in Europe and USD 664 million per year in the USA.
Bionanoplus has chosen firstly the PRRSV vaccines market due to the combination of it being a big market with a clear need to solve a problem and the capacity of the company to cover these needs with SAP-Nano technology.
The general objective of the Project was to test the economic feasibility of this new vaccination technology in an interesting industry (swine producers) and to prepare the launch of this technology on to the market.
The Project has been developed as planned, in terms of deadlines, budgets, actions, and results obtained.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

Thanks to the market research, Bionanoplus have found a partner to guarantee and validate the source of antigen supply for the production of the vaccines. This partner will collaborate with Bionanoplus in the final development and commercialization of the SAP-Nano PRRSV vaccine. We have also design a thoroughly strategy to approach potential clients, preparing the commercial and marketing material to address the international market. We have established the road map to commercialisation. Finally, the business model has been designed employing the Canvas methodology, along with the alliance, and business and marketing strategies. The company has undertaken a very important strategic reflection, involving the whole organization. As a result, we have development of a comprehensive business plan, which includes an economic & financial plan for the next four years

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

With its breakthrough technology Bionanoplus will contribute to improving the competitiveness of the vaccine manufacturer sector in Europe.
Apart from improving animal health and productivity, veterinary vaccines have a significant impact on public health through reductions in the use of veterinary pharmaceuticals and hormones and their residues in the human food chain.
The Project will generate qualified job positions at Bionanoplus as well as positions at European vaccine manufacturers.
Promoters expects to demonstrate that Bionanoplus will be soon an internationally recognized company within the field of polymeric nanoencapsulation solutions to develop innovative vaccines.

Bionanoplus Logo